Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure

BACKGROUND: This study aimed to determine the maximum tolerated dose (MTD), dose-limiting toxicity, and efficacy of second-line chemotherapy with FOLFIRINOX after gemcitabine (GEM)-based chemotherapy failure in metastatic pancreatic cancer (MPC). METHODS: We studied 18 histopathologically proven MPC...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Noritoshi, Shimamura, Takeshi, Tokuhisa, Motohiko, Goto, Ayumu, Endo, Itaru, Ichikawa, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428587/
https://www.ncbi.nlm.nih.gov/pubmed/28489753
http://dx.doi.org/10.1097/MD.0000000000006769

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428587/
https://www.ncbi.nlm.nih.gov/pubmed/28489753
http://dx.doi.org/10.1097/MD.0000000000006769

Ejemplares similares